Low expression Macrophage Migration Inhibitory Factor (MIF) alleles and tuberculosis in HIV infected South Africans [0.03%]
HIV感染者中低表达巨噬细胞炎症蛋白等位基因与结核病的关系研究
Duncan Reid,Sheela Shenoi,Ravesh Singh et al.
Duncan Reid et al.
Host immunity is crucial for controlling M. tuberculosis infection. Functional polymorphisms in the cytokine macrophage migration inhibitory factor (MIF) show global population stratification, with the highest prevalence of low expression M...
Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study [0.03%]
首个细胞因子释放测定平台定性和验证参考抗体集合的开发——国际协作研究报道
Sandrine Vessillier,Madeline Fort,Lynn O&#x;Donnell et al.
Sandrine Vessillier et al.
Immunomodulatory therapeutics such as monoclonal antibodies (mAb) carry an inherent risk of undesired immune reactions. One such risk is cytokine release syndrome (CRS), a rapid systemic inflammatory response characterized by the secretion ...
Unravelling the unsolved paradoxes of cytokine families in host resistance and susceptibility to Leishmania infection [0.03%]
细胞因子家族在宿主抗利什曼原虫感染中的抵抗和易感性中未解悖论的破解
Bernard Ong&#x;ondo Osero,Raphael Taiwo Aruleba,Frank Brombacher et al.
Bernard Ong&#x;ondo Osero et al.
Leishmaniasis is a neglected disease caused by protozoan parasites of the genus Leishmania. Successful clearance of Leishmania relies on a robust human immune response and various cytokines have been implicated in resistance and susceptibil...
New variants in NLRP3 inflammasome genes increase risk for asthma and Blomia tropicalis-induced allergy in a Brazilian population [0.03%]
NLRP3炎性小体基因的新变异增加了巴西人群哮喘和Blomia tropicalis诱导的过敏的风险
Gerson de A Queiroz,Raimon R da Silva,Anaque de O Pires et al.
Gerson de A Queiroz et al.
Atopic asthma is a chronic lung disease of lower airways caused mainly due to action of T-helper (Th) 2 type cytokines, eosinophilic inflammation, mucus hypersecretion and airway remodelling. Interleukin (IL)-33 increases type 2 immunity po...
Tocilizumab for severe COVID-19 related illness - A community academic medical center experience [0.03%]
托西珠单抗用于严重COVID-19相关疾病的一种社区学术医疗中心的经验
Kapil S Meleveedu,John Miskovsky,Joseph Meharg et al.
Kapil S Meleveedu et al.
The SARS-CoV-2 virus responsible for the COVID-19 pandemic can result in severe or fatal disease in a subset of infected patients. While the pathogenesis of severe COVID-19 disease has yet to be fully elucidated, an overexuberant and harmfu...
SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc [0.03%]
SARS-CoV-2和COVID-19： IL-6是ARDS发病的“病理性因素”吗？除了托珠单抗，还有哪些选择？SGP130Fc
Giuseppe Magro
Giuseppe Magro
Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients,...
MIF mediates bladder pain, not inflammation, in cyclophosphamide cystitis [0.03%]
MIF在环磷酰胺膀胱炎中介导膀胱痛而不是炎症
Fei Ma,Dimitrios E Kouzoukas,Katherine L Meyer-Siegler et al.
Fei Ma et al.
Macrophage migration inhibitory factor (MIF), a proinflammatory mediator, is recognized as a player in inflammatory and neuropathic pain. Cyclophosphamide (CYP) results in bladder inflammation and pain and it's a frequently used animal mode...